Phase 1/2 Study of Atrasentan Combined with Pegylated Liposomal Doxorubicin in Platinum-Resistant Recurrent Ovarian Cancer by Witteveen, Petronella O., van der Mijn, Koen J.C., Los, Maartje, Kronemeijer, Roelien H., Groenewegen, Gerard, Voest, Emile E.

Get full text

Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor–driven Programs by Linder, Simon, Severson, Tesa M., van der Mijn, Koen J.C., Nevedomskaya, Ekaterina, Siefert, Joseph C., Stelloo, Suzan, Pomerantz, Mark M., Freedman, Matthew L., van der Poel, Henk, Jerónimo, Carmen, Henrique, Rui, Bergman, Andries M., Zwart, Wilbert

Get full text

Treating Primary Node-Positive Prostate Cancer: A Scoping Review of Available Treatment Options by Zuur, Lotte G, de Barros, Hilda A, van der Mijn, Koen J C, Vis, André N, Bergman, Andries M, Pos, Floris J, van Moorselaar, Jeroen A, van der Poel, Henk G, Vogel, Wouter V, van Leeuwen, Pim J

Get full text

Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse by Chen, Mengnuo, Mainardi, Sara, Lieftink, Cor, Velds, Arno, de Rink, Iris, Yang, Chen, Kuiken, Hendrik J., Morris, Ben, Edwards, Finn, Jochems, Fleur, van Tellingen, Olaf, Boeije, Manon, Proost, Natalie, Jansen, Robin A., Qin, Shifan, Jin, Haojie, Koen van der Mijn, J.C., Schepers, Arnout, Venkatesan, Subramanian, Qin, Wenxin, Beijersbergen, Roderick L., Wang, Liqin, Bernards, René

Get full text